DYNE THERAPEUTICS INC
NASDAQ: DYN (Dyne Therapeutics, Inc.)
Last update: 13 hours ago9.40
-0.62 (-6.19%)
| Previous Close | 10.02 |
| Open | 10.10 |
| Volume | 5,559,631 |
| Avg. Volume (3M) | 2,239,104 |
| Market Cap | 1,068,159,552 |
| Price / Book | 2.16 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 15 May 2025 |
| Diluted EPS (TTM) | -3.37 |
| Total Debt/Equity (MRQ) | 3.81% |
| Current Ratio (MRQ) | 15.60 |
| Operating Cash Flow (TTM) | -292.37 M |
| Levered Free Cash Flow (TTM) | -189.47 M |
| Return on Assets (TTM) | -50.20% |
| Return on Equity (TTM) | -88.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Dyne Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 101.05% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 31 Dec 2024 | 8,019,354 |
| Janus Henderson Group Plc | 31 Dec 2024 | 7,379,309 |
| Fcpm Iii Services B.V. | 31 Dec 2024 | 5,462,846 |
| Rtw Investments, Lp | 31 Dec 2024 | 5,218,641 |
| Tcg Crossover Management, Llc | 31 Dec 2024 | 2,650,150 |
| Holocene Advisors, Lp | 31 Dec 2024 | 2,348,161 |
| Vr Adviser, Llc | 31 Dec 2024 | 2,173,913 |
| Deep Track Capital, Lp | 31 Dec 2024 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Chardan Capital, 431.92%) | Buy |
| 50.00 (BMO Capital, 431.92%) | Buy | |
| 50.00 (Scotiabank, 431.92%) | Buy | |
| Median | 49.00 (421.28%) | |
| Low | 17.00 (JP Morgan, 80.85%) | Hold |
| Average | 42.17 (348.62%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 12.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 09 May 2025 | 50.00 (431.91%) | Buy | 11.99 |
| 17 Mar 2025 | 50.00 (431.91%) | Buy | 12.31 | |
| HC Wainwright & Co. | 09 May 2025 | 38.00 (304.26%) | Buy | 11.99 |
| 17 Mar 2025 | 46.00 (389.36%) | Buy | 12.31 | |
| JP Morgan | 21 Mar 2025 | 17.00 (80.85%) | Hold | 12.08 |
| BMO Capital | 12 Mar 2025 | 50.00 (431.91%) | Buy | 12.36 |
| Scotiabank | 07 Mar 2025 | 50.00 (431.91%) | Buy | 12.40 |
| Piper Sandler | 28 Feb 2025 | 48.00 (410.64%) | Buy | 13.61 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |